Trial Profile
Phase II randomised placebo controlled NEOadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive BLADder cancEr
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms NEOBLADE version: 2
- 11 Apr 2022 Primary endpoint (Complete clinical response) has not been met according to the results published in the Lancet Oncology
- 11 Apr 2022 Results assessing the effect of adding nintedanib to neoadjuvant chemotherapy on response and survival in muscle-invasive bladder cancer published in the Lancet Oncology
- 07 Dec 2015 Accrual to date is 23% according to the United Kingdom Clinical Research Network record.